Leadership Team

Jack is a renowned cardiologist with more than 20 years of drug development experience across Phase 1–4 programs in cardiology, hematology, vascular medicine, and neurology. Most recently, he was head of global development, cardiovascular & metabolism at Janssen Pharmaceutical Companies of Johnson & Johnson and prior to this, chief medical officer at Portola. Before Portola, Jack spent more than 15 years at Bristol-Myers Squibb (BMS) in roles of increasing responsibility culminating as vice president and cardiovascular therapeutic area head. At BMS, Jack was the cross-functional team leader for the development of one of the most successful cardiovascular drugs, ELIQUIS® (apixaban), helping bring it from Phase 1 to global approvals. Before joining industry, he was an associate professor at The Johns Hopkins University School of Medicine. Jack received his M.D. from the University of Virginia School of Medicine, M.S. in electrical engineering from MIT, and a B.S. in biomedical engineering from Brown University. He completed his residency at the University of North Carolina and a fellowship in cardiology at The Johns Hopkins Hospital, including attending on electrophysiology service.